Tejara Capital Ltd Trims Stake in Schrödinger, Inc. (NASDAQ:SDGR)

Tejara Capital Ltd lowered its position in Schrödinger, Inc. (NASDAQ:SDGR) by 21.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,907 shares of the company’s stock after selling 22,328 shares during the quarter. Schrödinger comprises about 1.0% of Tejara Capital Ltd’s portfolio, making the stock its 27th largest position. Tejara Capital Ltd owned 0.11% of Schrödinger worth $1,561,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. KBC Group NV raised its stake in shares of Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after acquiring an additional 783 shares during the period. Paradigm Asset Management Co. LLC purchased a new stake in shares of Schrödinger in the fourth quarter valued at $50,000. GAMMA Investing LLC raised its stake in shares of Schrödinger by 87.5% in the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock valued at $54,000 after acquiring an additional 1,305 shares during the period. Quarry LP raised its stake in shares of Schrödinger by 1,150.0% in the third quarter. Quarry LP now owns 2,825 shares of the company’s stock valued at $52,000 after acquiring an additional 2,599 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Schrödinger in the third quarter valued at $102,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SDGR. KeyCorp upped their price target on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Piper Sandler cut their price target on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.29.

Insiders Place Their Bets

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at approximately $599,357.44. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 8.60% of the stock is owned by company insiders.

Schrödinger Price Performance

Shares of Schrödinger stock opened at $23.73 on Tuesday. Schrödinger, Inc. has a 1 year low of $16.67 and a 1 year high of $29.15. The firm’s 50-day moving average is $22.75 and its two-hundred day moving average is $20.72. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -10.14 and a beta of 1.62.

Schrödinger (NASDAQ:SDGR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. On average, equities analysts expect that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.